There are currently 378 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Spectrum Health at Butterworth Campus, Helen DeVos Children's Hospital at Spectrum Health, CCOP - Grand Rapids and Mercy Health Saint Mary's. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Recruiting
The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Spinal Cord Injury
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
All
Ages:
31 years and below
Trial Updated:
04/04/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Neuroblastoma
PV Loop & Coarctation Study
Recruiting
Coarctation of the aorta accounts for 4-7% of all congenital heart disease. While stent therapy, when feasible, is the standard of care for coarctation, it may not completely improve the work (and afterload) of the heart due to its effects on the elasticity of the aorta. This study will provide the information needed to understand the effects of current management on the cardiac mechanics and work.
Gender:
All
Ages:
6 years and above
Trial Updated:
04/04/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Coarctation of Aorta
Pompe Pregnancy Sub-Registry
Recruiting
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standa... Read More
Gender:
Female
Ages:
All
Trial Updated:
04/04/2024
Locations: Spectrum for Health Site Number : 840019, Grand Rapids, Michigan
Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
A Study to Assess EN3835 in the Treatment of Plantar Fasciitis (PFA)
Recruiting
This study will assess the efficacy, safety, and tolerability of 2 different doses of EN3835 compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2024
Locations: Endo Site 19, Grand Rapids, Michigan
Conditions: Plantar Fasciitis
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
All
Ages:
22 years and below
Trial Updated:
04/04/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Neuroblastoma
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
04/04/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Neuroblastoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Recruiting
Patients with Small Cell Lung Cancer, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Gender:
All
Ages:
16 years and above
Trial Updated:
04/03/2024
Locations: Corewell Health-BAMF Health, Grand Rapids, Michigan
Conditions: SCLC, Malignant Melanoma, Sarcoma
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan +2 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
Recruiting
The purpose of this trial is to investigate the safety and efficacy of acasunlimab (also known as GEN1046) as monotherapy and in combination with pembrolizumab in patients with non-small cell lung cancer who have progressed during or after treatment of previous standard of care
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Cancer & Hematology Centers of Western Michigan CHCWM P.C., Grand Rapids, Michigan
Conditions: Non Small Cell Lung Cancer Metastatic
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Recruiting
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: South Texas Accelerated Research Therapeutics, Grand Rapids, Michigan
Conditions: Metastatic Cancer, Solid Tumor, Colorectal Cancer, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
Recruiting
This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 ([18F]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: BAMF Health, Inc., Grand Rapids, Michigan
Conditions: Radiotracer, Hypertension, Cholesterol